Abstract:Thrombotic thrombocytopenic purpura (TTP) is a particular form of thrombotic microangiopathy typically characterized by microangiopathic hemolytic anemia, profound peripheral thrombocytopenia, and a severe deficiency of the von Willebrand factor-cleaving protease ADAMTS13 (acronym for A Disintegrin And Metalloproteinase with ThromboSpondin-1 motifs [13th member of the family]). ADAMTS13 deficiency is usually severe (<10% of normal activity) and results from autoantibodies directed to ADAMTS13 (acquired TTP) or from biallelic mutations of the encoding gene. In some cases, acquired TTP occurs in association with specific conditions that must be identified for appropriate management: a HIV infection, a connective tissue disease, a pregnancy, a cancer or a treatment with antiplatelet agents. TTP requires a rapid diagnosis and an adapted management in emergency, which allows current remission rates of 80 to 90%. Maximal measures of resuscitation may be required. Daily sessions of therapeutical plasma exchange (TPE) until durable platelet count recovery remain the basis of management of acquired TTP. In the last few years, the anti-CD20 monoclonal antibody rituximab has been increasingly used in patients with a suboptimal response to standard treatment, such as those with refractory disease (∼10% of cases) or an exacerbation of the disease despite intensive TPE (∼50% of cases). Rituximab prevents 1-year but not long-term relapses. Further studies should specify the optimal schedule of rituximab administration and its role as a prophylactic treatment in asymptomatic patients with severe acquired ADAMTS13 deficiency that persists even in disease remission. In hereditary TTP, also known as Upshaw-Schulman syndrome (USS), a diagnosis early in life is mandatory. Prophylactic infusions of plasma should be performed in chronic relapsing forms to prevent long-term organ complications, which have to be assessed accurately and regularly. In the upcoming years, new targeted therapies evaluated through international trials should further improve the management of these diseases. Consensual guidelines for the treatment of very specific and rare situations (such as management during pregnancy in USS patients and prevention of relapses in chronic relapsing acquired TTP) should arise from the shared experience of national groups.

A "backup plan" for ADAMTS13 deficiency in TTP

VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP

The Highs and Lows of ADAMTS13 Activity

[The Dynamic Analysis and the Clinical Significance of Vascular Endothelial Cell Markers and Hemolysis Parameters in Thrombotic Thrombocytopenic Purpura].

Plasmin-cleaved Von Willebrand Factor as a biomarker for microvascular thrombosis

[A Clinical Study of Congenital Thrombotic Thrombocytopenic Purpura].

[Identification of Two Novel Mutations in ADAMTS13 Gene in a Patient with Hereditary Thrombotic Thrombocytopenic Purpura].

Laboratory Testing for ADAMTS13 for Thrombotic Thrombocytopenia Purpura and Beyond

The utility of patient characteristics in predicting severe ADAMTS13 deficiency and response to plasma exchange

Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura

[Advances in the treatment of thrombotic thrombocytopenic purpura]

Pathological Mechanisms and Novel Testing Methods in Thrombotic Thrombocytopenic Purpura

Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura

Therapy of Hereditary Ttp with Adamts13 Deficiency - A Case Report and Review of the Literature.

Diagnostic Challenges in a Case of Immune-Mediated Thrombotic Thrombocytopenic Purpura With Severe ADAMTS13 Deficiency

Excessive cleavage of von Willebrand factor multimers by ADAMTS13 may predict the progression of transplant-associated thrombotic microangiopathy

Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura

Novel mechanisms of action of emerging therapies of hereditary thrombotic thrombocytopenic purpura

ADAMTS13 Biomarkers in Management of Immune Thrombotic Thrombocytopenic Purpura

Linear relationship between ADAMTS13 activity and platelet dynamics even before severe thrombocytopenia

Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA Research Collaborative